CF
CATX icon

Corebridge Financial’s Perspective Therapeutics CATX Stock Holding History

Corebridge Financial’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,483
Closed -$56.4K – 474
2025
Q1 		$56.4K Sell
26,483
-393
-1% -$1.18K ﹤0.01% 2690
2024
Q4 		$85.7K Sell
26,876
-2,029
-7% -$16.6K ﹤0.01% 2620
2024
Q3 		$386K Buy
28,905
+3,572
+14% +$47.5K ﹤0.01% 1867
2024
Q2 		$253K Buy
+25,333
New +$366K ﹤0.01% 2061

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corebridge Financial's CATX Position: Q2 2025 in Review

Corebridge Financial sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 26,483 shares — an estimated $56.4K sold.

Corebridge Financial first reported a position in CATX in Q2 2024 and held it in 4 quarters. The position peaked at $386K in Q3 2024. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

  • Corebridge Financial reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 26,483 Perspective Therapeutics shares in Q2 2025, an estimated $56.4K.
  • Corebridge Financial first reported a position in Perspective Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Perspective Therapeutics position peaked at $386K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.